Citadel Advisors’s TriSalus Life Sciences TLSI Stock Holding History

Citadel Advisors’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-26,580	Closed	-$147K	–	15086
2025 Q1	$147K	Buy	+26,580	New	+$142K	﹤0.01%	10910
2022 Q2	–	Sell	-10,133	Closed	-$99K	–	14102
2022 Q1	$99K	Sell	10,133 -242,299	-96%	-$2.39M	﹤0.01%	12294
2021 Q4	$2.49M	Sell	252,432 -2,209	-0.9%	-$21.9K	﹤0.01%	5735
2021 Q3	$2.53M	Sell	254,641 -307,682	-55%	-$3.01M	﹤0.01%	5781
2021 Q2	$5.49M	Buy	562,323 +1,279	+0.2%	+$12.5K	﹤0.01%	4235
2021 Q1	$5.42M	Buy	+561,044	New	+$5.69M	﹤0.01%	4082

Other funds holding TLSI

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WAP

Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors's TLSI Position: Q2 2025 in Review

Citadel Advisors sold out of TriSalus Life Sciences (TLSI) in Q2 2025, closing a stake of 26,580 shares — an estimated $147K sold.

Citadel Advisors first reported a position in TLSI in Q1 2021 and held it in 6 quarters. The position peaked at $5.49M in Q2 2021. 48 funds tracked by Wall St. Rank hold TLSI as of Q2 2025.

Citadel Advisors reported no remaining TriSalus Life Sciences position as of Q2 2025 after selling out during the quarter.
Citadel Advisors sold 26,580 TriSalus Life Sciences shares in Q2 2025, an estimated $147K.
Citadel Advisors first reported a position in TriSalus Life Sciences in Q1 2021 and held it in 6 quarters.
Citadel Advisors's TriSalus Life Sciences position peaked at $5.49M in Q2 2021.
48 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.